Enasidenib Indian version price information

Enasidenib is a targeted therapy drug mainly used to treat patients with acute myeloid leukemia (AML) carrying IDH2 mutations, especially for relapsed or refractory cases. The drug was developed by a foreign pharmaceutical company and has not yet been officially launched in China. Therefore, it is not included in the scope of national medical insurance reimbursement. If patients need to use it, they usually need to purchase it through overseas channels.

There is currently no Indian generic version of ensidipine on the market, and Indian pharmaceutical companies have not yet launched a generic version of the drug. This means that patients cannot obtain low-cost alternatives to the drug from Indian sources and can only rely on original drugs or generic versions from other countries for treatment. Due to the lack of the price advantage of Indian generic drugs, patients have relatively limited options and an increased financial burden.

In overseas markets, the price of ensidipi plain medicine is relatively high. Taking the common specifications of 50mg30 tablets or 100mg30 tablets as an example, the price per box is usually around 30 more than 10,000 yuan. The specific price will be affected by exchange rate fluctuations and the supplying country. For patients who require long-term treatment, this is undoubtedly a huge expense and often becomes an important factor in patients' decisions about whether to take medication.

In order to relieve financial pressure, some patients choose to use generic drugs produced by Lucius Pharmaceutical Factory in Laos. This version is 50mg*30 tablets, and each box sells for about more than 1,000 yuan. Although the price is relatively low, its active ingredients are consistent with the original drug, and there is no obvious difference in the treatment mechanism. However, patients still need to purchase it through formal channels and use it under the guidance of professional doctors to ensure safety and efficacy.

Reference materials:https://www.idhifa.com/

xa0